Company intelligence / Profile preview

Incite

Wilmington, Delaware, United States

Ownership: Private
Employees: ~2500
Development stage: Other

Overview

Incyte has multiple commercial products such as ruxolitinib (JAKAFI/OPZELURA), pemigatinib (PEMAZYRE), tafasitamab (MONJUVI), retifanlimab (ZYNYZ), axatilimab (NIKTIMVO), and capmatinib (TABRECTA) through partners. New programs in oncology, inflammation, and autoimmunity are in mid- to late-stage clinical trials. Clinical results have supported first-in-class approvals for various hematological, oncological, and immunological diseases

Therapeutic areas: HematologyImmunologyDermatologyOncology
Modalities: Small moleculeMonoclonal antibodyAntibody-drug conjugateTopical drug (e.g., topical JAK inhibitor)Oral drug
Industry: Biotech

Partnerships

Novartis (marketing partnership for JAKAVI/capmatinib)Eli Lilly (baricitinib/OLUMIANT partnership)MorphoSys (tafasitamab collaboration)

Beyond the preview

Go deeper on Incite.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Incite.

Explore the full profile